CN112386615B - 抑制幽门螺旋杆菌感染的副干酪乳杆菌jlpf-176的应用及产品 - Google Patents
抑制幽门螺旋杆菌感染的副干酪乳杆菌jlpf-176的应用及产品 Download PDFInfo
- Publication number
- CN112386615B CN112386615B CN202110066239.9A CN202110066239A CN112386615B CN 112386615 B CN112386615 B CN 112386615B CN 202110066239 A CN202110066239 A CN 202110066239A CN 112386615 B CN112386615 B CN 112386615B
- Authority
- CN
- China
- Prior art keywords
- lactobacillus paracasei
- jlpf
- product
- powder
- helicobacter pylori
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000186605 Lactobacillus paracasei Species 0.000 title claims abstract description 53
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 14
- 206010019375 Helicobacter infections Diseases 0.000 title abstract description 8
- 241000590002 Helicobacter pylori Species 0.000 claims abstract description 25
- 229940037467 helicobacter pylori Drugs 0.000 claims abstract description 25
- 238000004321 preservation Methods 0.000 claims abstract description 18
- 241000186660 Lactobacillus Species 0.000 claims abstract description 16
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 16
- 208000007107 Stomach Ulcer Diseases 0.000 claims abstract description 7
- 201000005917 gastric ulcer Diseases 0.000 claims abstract description 7
- 238000009629 microbiological culture Methods 0.000 claims abstract description 6
- 239000000843 powder Substances 0.000 claims description 34
- 239000007788 liquid Substances 0.000 claims description 13
- 230000001580 bacterial effect Effects 0.000 claims description 12
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 8
- 239000012153 distilled water Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 229920001817 Agar Polymers 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 239000001888 Peptone Substances 0.000 claims description 6
- 108010080698 Peptones Proteins 0.000 claims description 6
- 239000008272 agar Substances 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 235000019319 peptone Nutrition 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 4
- 235000015278 beef Nutrition 0.000 claims description 4
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 4
- 229910000396 dipotassium phosphate Inorganic materials 0.000 claims description 4
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 4
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims description 4
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 claims description 4
- 229920000136 polysorbate Polymers 0.000 claims description 4
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 claims description 4
- 239000001393 triammonium citrate Substances 0.000 claims description 4
- 235000011046 triammonium citrate Nutrition 0.000 claims description 4
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 3
- 238000013329 compounding Methods 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000004211 gastric acid Anatomy 0.000 abstract description 6
- 230000004083 survival effect Effects 0.000 abstract description 6
- 244000005700 microbiome Species 0.000 abstract description 4
- 238000012360 testing method Methods 0.000 description 25
- 241000699670 Mus sp. Species 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 5
- 210000001156 gastric mucosa Anatomy 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 206010067484 Adverse reaction Diseases 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 230000008029 eradication Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108010009004 proteose-peptone Proteins 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 1
- 241001468155 Lactobacillaceae Species 0.000 description 1
- 241001112724 Lactobacillales Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 241000212749 Zesius chrysomallus Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000012984 antibiotic solution Substances 0.000 description 1
- 229940006383 azithromycin 10 mg/ml Drugs 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 description 1
- 229960004157 rabeprazole Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D13/00—Finished or partly finished bakery products
- A21D13/06—Products with modified nutritive value, e.g. with modified starch content
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G3/366—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing microorganisms, enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G9/00—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor
- A23G9/32—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds
- A23G9/36—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G9/363—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing microorganisms, enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/70—Clarifying or fining of non-alcoholic beverages; Removing unwanted matter
- A23L2/84—Clarifying or fining of non-alcoholic beverages; Removing unwanted matter using microorganisms or biological material, e.g. enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/165—Paracasei
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/245—Lactobacillus casei
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明涉及微生物技术领域,具体是抑制幽门螺旋杆菌感染的副干酪乳杆菌JLPF‑176的应用及产品,所述应用为在制备抑制幽门螺旋杆菌生长的产品以及治疗胃溃疡的产品中的应用,所述副干酪乳杆菌JLPF‑176的分类命名为副干酪乳杆菌Lactobacillus paracasei,保藏号为CGMCC NO.18043,保藏日期为2019年6月27日,保藏单位为中国微生物菌种保藏管理委员会普通微生物中心,地址:北京市朝阳区北辰西路1号院3号,中国科学院微生物研究所,邮编:100101。本发明使用的副干酪乳杆菌JLPF‑176具有强的胃酸存活率,能够有效抑制幽门螺旋杆菌生长。
Description
技术领域
本发明涉及微生物技术领域,具体的说是抑制幽门螺旋杆菌感染的副干酪乳杆菌JLPF-176的应用及产品。
背景技术
乳酸杆菌是一群对机体有益的微生物,它具有维护人体健康和调节免疫功能的作用。副干酪乳杆菌能维持机体特异性和非特异性的免疫机制。
中文名称:副干酪乳杆菌;拉丁名称:Lactobacillus paracasei;属名:Lactobacillus;种名:paracasei;兼性厌氧、不运动、无芽孢的杆菌或长杆菌,革兰氏阳性,过氧化氢酶阴性。
应用领域一般为:乳制品、保健食品、饮料、饼干、糖果、冰淇淋。
副干酪乳杆菌经过发酵后不仅可为食品增加发酵风味物质,还能保护食品原有颜色、促进矿物质吸收、产生人体所必需的多种维生素、乳酸菌素、消化酶等物质,从而具有健胃、助消化及提高机体免疫能力的功效。
幽门螺杆菌病是一种螺旋形、微厌氧、对生长条件要求十分苛刻的细菌。1983年首次从慢性活动性胃炎患者的胃黏膜活检组织中分离成功,是目前所知能够在人胃中生存的唯一微生物种类。2017年10月27日,世界卫生组织国际癌症研究机构公布的致癌物清单初步整理参考,幽门螺杆菌(感染)在一类致癌物清单中。
随着人们生活水平的不断提高,以及对于幽门螺杆菌的日渐认识,一旦发现阳性,都会心事重重,恨不得马上就能把这个菌消灭殆尽。对于幽门螺杆菌的控制采用抗生素联合用药,并且容易反复,现在滥用抗生素的问题泛滥,如何有效并且绿色的抑制该菌,成为困扰携带该菌的人群的一大难题。
发明内容
本发明为抑制幽门螺杆菌的问题,提供了一种有效的并且绿色的产品,具体为一种抑制幽门螺旋杆菌感染的副干酪乳杆菌JLPF-176的应用及产品。
第一方面,本发明提供一种抑制幽门螺旋杆菌感染的副干酪乳杆菌JLPF-176的应用,所述应用为副干酪乳杆菌在制备抑制幽门螺旋杆菌生长的产品以及治疗胃溃疡的产品中的应用,所述副干酪乳杆菌JLPF-176的分类命名为副干酪乳杆菌Lactobacillus paracasei,保藏号为CGMCC NO.18043,保藏日期为2019年6月27日,保藏单位为中国微生物菌种保藏管理委员会普通微生物中心,地址:北京市朝阳区北辰西路1号院3号,中国科学院微生物研究所,邮编:100101。
第二方面,本发明提供一种由副干酪乳杆菌JLPF-176制备的抑制幽门螺旋杆菌生长的产品。
第三方面,本发明提供一种由副干酪乳杆菌JLPF-176制备的治疗胃溃疡的产品。
进一步的,所述产品为内服制剂。
进一步的,所述产品含有副干酪乳杆菌粉。
进一步的,所述产品为副干酪乳杆菌粉与低聚异麦芽糖混合复配制成。
进一步的,所述菌粉的活菌数为50亿/g-150亿/g、250亿/g、500亿/g、1000亿/g。
进一步的,所述副干酪乳杆菌粉的制备方法为,将副干酪乳杆菌JLPF-176接种到MRS液体培养基平板中,1%接种量,在37℃条件下,兼性厌氧培养8-12小时,MRS菌液经过离心,真空冷冻干燥,获得副干酪乳杆菌粉。
进一步的,所述MRS液体培养基为:蛋白胨10g、牛肉粉5g、酵母粉4g、K2HPO4•7H2O2g、柠檬酸三铵2g、CH3COONa•3H2O 5g、葡萄糖20g、吐温80 1mL、MgSO4•7H2O 0.2g、MnSO4•4H2O 0.05g、琼脂15g、蒸馏水1000mL。
本发明的有益效果在于,
本发明通过分离获得的副干酪乳杆菌JLPF-176,具有强的胃酸存活率,能够有效抑制幽门螺旋杆菌生长的能力,进而对胃溃疡有很好的疗效,并有较好的临床效果。
本发明还提供由副干酪乳杆菌JLPF-176制备的产品,该产品中含有副干酪乳杆菌JLPF-176菌粉,方便使用,便于储存,被广大的人群所接受,可以方便的用于日常保健,以及预防和治疗胃溃疡等疾病的应用。
附图说明
为了更清楚地说明本发明实施例或现有技术中的技术方案,下面将对实施例或现有技术描述中所需要使用的附图作简单地介绍,显而易见地,对于本领域普通技术人员而言,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。
图1为乳杆菌粉通过模拟胃酸存活率对照图;
图2为副干酪乳杆菌JLPF-176对幽门螺旋杆菌抑制实验的抑菌效果直径对比图;
图3为乳杆菌对胃粘膜修复的影响中对照组和实验组的胃粘膜组织图;
图4为不良反应发生率结果图;
图5为对幽门螺旋杆菌的根除率效果图。
具体实施方式
为了使本技术领域的人员更好地理解本发明中的技术方案,下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都应当属于本发明保护的范围。
本发明的一种副干酪乳杆菌,所述副干酪乳杆菌的菌株号为JLPF-176,其分类命名为副干酪乳杆菌Lactobacillus paracasei,保藏号为:CGMCC NO.18043,保藏日期为2019年6月27日,保藏单位为中国微生物菌种保藏管理委员会普通微生物中心,地址:北京市朝阳区北辰西路1号院3号,中国科学院微生物研究所,邮编:100101。
实施例1
(一)菌种分离纯化
平板培养基:蛋白胨10g、牛肉粉5g、酵母粉4g、K2HPO4•7H2O 2g、柠檬酸三铵2g、CH3COONa•3H2O 5g、葡萄糖20g、吐温80 1mL、MgSO4•7H2O 0.2g、MnSO4•4H2O 0.05g、琼脂15g、蒸馏水1000mL。
菌株的分离
1.山东省青州市西股村对无家族遗传病史的哺乳期女性进行母乳采样,取样过程戴手套消毒操作,避免接触样品以防污染。取出样品后立即冷藏盒保存,并编号记录。
2.对样品液体做十倍梯度稀释,每个梯度取100μL均匀涂布于MRS固体平板培养基上,随后取出置于厌氧罐中,37℃厌氧培养过夜。
次日可见平板上长有形态大小各异的菌落,挑取若干乳酸菌的特征菌落作二代划线纯化处理,平板厌氧活化1天,得培养物,随后做菌株鉴定。
(二)菌种鉴定
1.鉴定单位:生工生物工程(上海)股份有限公司。
2.引物
引物序列
27F:5'-AGAGTTTGATCMTGGCTCAG-3',
1492R:5'-GGTTACCTTGTTACGACTT-3'。
3.鉴定的序列
TCAGGATGAACGCTGGCGGCGTGCCTAATACATGCAAGTCGAACGAGTTCTCGTTGATGATCGGTGCTTGCACCGAGATTCAACATGGAACGAGTGGCGGACGGGTGAGTAACACGTGGGTAACCTGCCCTTAAGTGGGGGATAACATTTGGAAACAGATGCTAATACCGCATAGATCCAAGAACCGCATGGTTCTTGGCTGAAAGATGGCGTAAGCTATCGCTTTTGGATGGACCCGCGGCGTATTAGCTAGTTGGTGAGGTAATGGCTCACCAAGGCGATGATACGTAGCCGAACTGAGAGGTTGATCGGCCACATTGGGACTGAGACACGGCCCAAACTCCTACGGGAGGCAGCAGTAGGGAATCTTCCACAATGGACGCAAGTCTGATGGAGCAACGCCGCGTGAGTGAAGAAGGCTTTCGGGTCGTAAAACTCTGTTGTTGGAGAAGAATGGTCGGCAGAGTAACTGTTGTCGGCGTGACGGTATCCAACCAGAAAGCCACGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGTGGCAAGCGTTATCCGGATTTATTGGGCGTAAAGCGAGCGCAGGCGGTTTTTTAAGTCTGATGTGAAAGCCCTCGGCTTAACCGAGGAAGCGCATCGGAAACTGGGAAACTTGAGTGCAGAAGAGGACAGTGGAACTCCATGTGTAGCGGTGAAATGCGTAGATATATGGAAGAACACCAGTGGCGAAGGCGGCTGTCTGGTCTGTAACTGACGCTGAGGCTCGAAAGCATGGGTAGCGAACAGGATTAGATACCCTGGTAGTCCATGCCGTAAACGATGAATGCTAGGTGTTGGAGGGTTTCCGCCCTTCAGTGCCGCAGCTAACGCATTAAGCATTCCGCCTGGGGAGTACGACCGCAAGGTTGAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCAACGCGAAGAACCTTACCAGGTCTTGACATCTTTTGATCACCTGAGAGATCAGGTTTCCCCTTCGGGGGCAAAATGACAGGTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTATGACTAGTTGCCAGCATTTAGTTGGGCACTCTAGTAAGACTGCCGGTGACAAACCGGAGGAAGGTGGGGATGACGTCAAATCATCATGCCCCTTATGACCTGGGCTACACACGTGCTACAATGGATGGTACAACGAGTTGCGAGACCGCGAGGTCAAGCTAATCTCTTAAAGCCATTCTCAGTTCGGACTGTAGGCTGCAACTCGCCTACACGAAGTCGGAATCGCTAGTAATCGCGGATCAGCACGCCGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACACCATGAGAGTTTGTAACACCCGAAGCCGGTGGCGTAACCCTTTTAGGGAGCGAGCCGTCTAAGGTGGGACAAATGATTAGGGTGAAGTCGT。
4.鉴定的结果
该菌株被鉴定为Lactobacillus paracasei(副干酪乳杆菌)。其分类单元为:Bacteria;Firmicutes;Bacilli;Lactobacillales;Lactobacillaceae;Lactobacillus。
实施例2 菌种产品制备
MRS液体培养基:蛋白胨10g、牛肉粉5g、酵母粉4g、K2HPO4•7H2O 2g、柠檬酸三铵2g、CH3COONa•3H2O 5g、葡萄糖20g、吐温80 1mL、MgSO4•7H2O 0.2g、MnSO4•4H2O 0.05g、琼脂15g、蒸馏水1000mL。
培养条件:1%接种量,37℃培养。
MRS菌液经过离心,真空冷冻干燥,获得菌粉。
再通过与低聚异麦芽糖混合复配成50亿/g、150亿/g、250亿/g、500亿/g、1000亿/g的菌粉。
低聚异麦芽糖:购自保龄宝生物股份有限公司。
实施例3 菌株耐酸能力的实验
模拟胃酸的配制:取9.5%盐酸16.4mL,加蒸馏水稀释,使pH值达到2.0,按照每100mL加入1.0g胃蛋白酶,混匀,0.22μm无菌滤膜过滤,现配现用。取副干酪乳杆菌JLPF-176菌株的100亿/g菌粉1g,转移到预热的装有9mL模拟胃液试管中,37℃、80r/min处理0.5h、1.5h、2h。对样品溶液进行梯度稀释,倾注法活菌计数,每个处理3个重复。
取其余三种乳杆菌菌株ATCC4356、ATCC4357、ATCC4796作为对照,菌株溶液配制方法与副干酪乳杆菌JLPF-176菌株相同。
根据上述操作方法,对菌株JLPF-176、ATCC4356、ATCC4357、ATCC4796进行模拟胃酸的存活率实验,存活率对照图具体见图1。结论:副干酪乳杆菌JLPF-176菌株在体外模拟胃酸实验时,存活率大大超过其他对照菌株。
实施例4 副干酪乳杆菌JLPF-176对幽门螺旋杆菌抑制实验
幽门螺旋杆菌平板培养(固体培养基)
蛋白胨5.0g、牛脑浸出粉4.0g、牛心浸出粉4.0g、酪蛋白胨16.0g、氯化钠5.0g、葡萄糖2.0g、磷酸氢二钠2.5g、琼脂13.5g、蒸馏水930mL,pH值7.4,25℃。
幽门螺旋杆菌液体培养基
蛋白胨5.0g、牛脑浸出粉4.0g、牛心浸出粉4.0g、酪蛋白胨16.0g、氯化钠5.0g、葡萄糖2.0g、磷酸氢二钠2.5g、蒸馏水930mL,pH值7.4,25℃。
实验步骤
采用单层琼脂平板扩散法。通过稀释控制菌数在106CFU/mL。吸取幽门螺旋杆菌菌液0.1mL于固体培养基平板上,用无菌涂抹棒涂布均匀,于超净工作台内通无菌空气,放置1h待表面的菌液固定在平板的表面后打孔,孔的直径8mm,孔深3mm,将0.2mL(108CFU/mL左右)乳酸菌样液注入孔内,不可溢出孔外。于37℃培养8h观察结果,测定抑菌圈直径,对比如图2所示。每个平板三个孔,做两个平板平行。
结论:副干酪乳杆菌JLPF-176菌株在抑制幽门螺旋杆菌方面,大大超过其他对照菌株。
实施例5 动物实验
选取36只BalBL/C小鼠,8-10周龄。随机分为3组,每组12只。实验分为空白组,模型组,JLPF-176组。各组小鼠先灌胃混合抗生素溶液(阿奇霉素10mg/mL、氨苄青霉素10mg/mL、庆大霉素1.2mg/mL)1周,用量为每天灌胃0.1mL。然后除空白组外,其余各组小鼠均灌胃幽门螺旋杆菌109CFU/mL,灌胃0.5mL,每隔2天灌胃1次,共灌胃4次。同时JLPF-176组小鼠灌胃108CFU/mL的JLPF-176菌液。
试验一:干预8天后,处死小鼠,剪取小鼠的胃组织,参照悉尼分级系统,将胃黏膜组织HE染色后进行切片,并进行胃Hp感染分级,Hp呈深红色,背景红色。对染色后各小鼠胃黏膜组织进行观察,并统计红点数。少于2个红点为Hp(-),2~10个红点为Hp(+),10~50个红点为Hp(++),多于50个红点为Hp(+++)。结果见表1,与空白组比较,模型组小鼠胃组织Hp感染的动物数明显增加;与模型组比较,JLPF-176组小鼠的Hp感染数量和程度显著减少,差异有统计学意义,说明JLPF-176有减轻幽门螺旋杆菌感染的能力。
表1 各组小鼠胃组织Hp感染情况比较(单位:只)
分组 | Hp(-) | Hp(+) | Hp(++) | Hp(+++) | 总数 |
空白组 | 11 | 1 | 0 | 0 | 12 |
模型组 | 0* | 1* | 5* | 6* | 12 |
JLPF-176组 | 4# | 3# | 3# | 2# | 12 |
注:与空白组比较,*P<0.01;与模型组比较,#P<0.05。
试验二:于小鼠眼眶静脉丛取血清,用ELISA的方法检测IL-1β、TNF-α的含量。结果见表2。幽门螺旋杆菌(Hp)感染可引起慢性消化道溃疡、胃炎等慢性上消化道疾病。由表2可知,在服用JLPF-176后,小鼠胃内的炎症因子IL-1β、TNF-α的表达减少,说明JLPF-176可减轻小鼠胃部的炎症反应。
表2 各组小鼠血清IL-1β、TNF-α水平比较
分组 | IL-1β(pg/mL) | TNF-α(ng/mL) |
空白组 | 106.54±12.65 | 85.98±3.11 |
模型组 | 219.89±14.98** | 254.87±1.55** |
JLPF-176组 | 155.98±13.54*# | 126.99±2.65# |
注:与空白组相比,*P<0.05,**p<0.01;与模型组相比,#P<0.05。
实施例6 临床试验
选取自愿接受联合治疗的成年幽门螺旋杆菌感染者180名。试验期间,每位患者仍然按照原来的生活饮食习惯不变。为了保证服用乳杆菌菌粉的活性,服用抗生素时间和乳杆菌粉的服药时间间隔2h。抗生素采用三联疗法,即雷贝拉唑每次20mg,每日1次;阿莫西林每次1.0g,每日2次;克拉霉素每次0.5g,每日2次。副干酪乳杆菌JLPF-176菌粉每天服用150亿有效活菌数。
试验一:乳杆菌对胃粘膜修复的影响
试验组:正常服用抗生素(三联疗法)+副干酪乳杆菌JLPF-176菌粉,
对照组:正常服用抗生素(三联疗法),
每组试验人数:90人,
试验内容:试验组每天按时服用抗生素2h后服用JLPF-176菌粉150亿有效活菌数,对照组正常服用抗生素即可。试验进行时间30天,检测胃粘膜组织损伤情况。
试验结果见图3,其中图3a为对照组,图3b为试验组,结论:副干酪乳杆菌JLPF-176对胃粘膜有明显的修复作用。
试验二:联合治疗后不良反应实验
试验组:试验一试验组患者,
对照组:试验一对照组患者,
每组试验人数:90人,
试验内容:服药过程中观察记录两组患者发生不良反应的人数。
试验结果见图4,表明:副干酪乳杆菌JLPF-176可以显著降低服用抗生素的不良反应发生率。
试验三:联合治疗对Hp根除率的实验
试验组:试验一试验组患者,
对照组:试验一对照组患者,
每组试验人数:90人,
试验内容:试验进行时间30天后,检查患者体内幽门螺旋杆菌是否成功根除。
试验结果见图5,表明:副干酪乳杆菌JLPF-176可以明显提高对幽门螺旋杆菌的根除率。
尽管通过参考附图并结合优选实施例的方式对本发明进行了详细描述,但本发明并不限于此。在不脱离本发明的精神和实质的前提下,本领域普通技术人员可以对本发明的实施例进行各种等效的修改或替换,而这些修改或替换都应在本发明的涵盖范围内/任何熟悉本技术领域的技术人员在本发明揭露的技术范围内,可轻易想到变化或替换,都应涵盖在本发明的保护范围之内。因此,本发明的保护范围应以权利要求所述的保护范围为准。
序列表
<110> 山东中科嘉亿生物工程有限公司
<120> 抑制幽门螺旋杆菌感染的副干酪乳杆菌JLPF-176的应用及产品
<130> 2021
<160> 3
<170> SIPOSequenceListing 1.0
<210> 1
<211> 20
<212> DNA
<213> 人工合成(引物)
<400> 1
agagtttgat cmtggctcag 20
<210> 2
<211> 19
<212> DNA
<213> 人工合成(引物)
<400> 2
ggttaccttg ttacgactt 19
<210> 3
<211> 1503
<212> DNA
<213> 副干酪乳杆菌(Lactobacillus paracasei)
<400> 3
tcaggatgaa cgctggcggc gtgcctaata catgcaagtc gaacgagttc tcgttgatga 60
tcggtgcttg caccgagatt caacatggaa cgagtggcgg acgggtgagt aacacgtggg 120
taacctgccc ttaagtgggg gataacattt ggaaacagat gctaataccg catagatcca 180
agaaccgcat ggttcttggc tgaaagatgg cgtaagctat cgcttttgga tggacccgcg 240
gcgtattagc tagttggtga ggtaatggct caccaaggcg atgatacgta gccgaactga 300
gaggttgatc ggccacattg ggactgagac acggcccaaa ctcctacggg aggcagcagt 360
agggaatctt ccacaatgga cgcaagtctg atggagcaac gccgcgtgag tgaagaaggc 420
tttcgggtcg taaaactctg ttgttggaga agaatggtcg gcagagtaac tgttgtcggc 480
gtgacggtat ccaaccagaa agccacggct aactacgtgc cagcagccgc ggtaatacgt 540
aggtggcaag cgttatccgg atttattggg cgtaaagcga gcgcaggcgg ttttttaagt 600
ctgatgtgaa agccctcggc ttaaccgagg aagcgcatcg gaaactggga aacttgagtg 660
cagaagagga cagtggaact ccatgtgtag cggtgaaatg cgtagatata tggaagaaca 720
ccagtggcga aggcggctgt ctggtctgta actgacgctg aggctcgaaa gcatgggtag 780
cgaacaggat tagataccct ggtagtccat gccgtaaacg atgaatgcta ggtgttggag 840
ggtttccgcc cttcagtgcc gcagctaacg cattaagcat tccgcctggg gagtacgacc 900
gcaaggttga aactcaaagg aattgacggg ggcccgcaca agcggtggag catgtggttt 960
aattcgaagc aacgcgaaga accttaccag gtcttgacat cttttgatca cctgagagat 1020
caggtttccc cttcgggggc aaaatgacag gtggtgcatg gttgtcgtca gctcgtgtcg 1080
tgagatgttg ggttaagtcc cgcaacgagc gcaaccctta tgactagttg ccagcattta 1140
gttgggcact ctagtaagac tgccggtgac aaaccggagg aaggtgggga tgacgtcaaa 1200
tcatcatgcc ccttatgacc tgggctacac acgtgctaca atggatggta caacgagttg 1260
cgagaccgcg aggtcaagct aatctcttaa agccattctc agttcggact gtaggctgca 1320
actcgcctac acgaagtcgg aatcgctagt aatcgcggat cagcacgccg cggtgaatac 1380
gttcccgggc cttgtacaca ccgcccgtca caccatgaga gtttgtaaca cccgaagccg 1440
gtggcgtaac ccttttaggg agcgagccgt ctaaggtggg acaaatgatt agggtgaagt 1500
cgt 1503
Claims (9)
1.一种副干酪乳杆菌JLPF-176的应用,其特征在于,所述应用为副干酪乳杆菌JLPF-176在制备抑制幽门螺旋杆菌生长的产品以及治疗胃溃疡的产品中的应用,所述副干酪乳杆菌JLPF-176的分类命名为副干酪乳杆菌Lactobacillus paracasei,保藏号为CGMCCNO.18043,保藏日期为2019年6月27日,保藏单位为中国微生物菌种保藏管理委员会普通微生物中心,地址:北京市朝阳区北辰西路1号院3号,中国科学院微生物研究所,邮编:100101。
2.一种副干酪乳杆菌JLPF-176制备得到的抑制幽门螺旋杆菌生长的产品,其特征在于,所述副干酪乳杆菌JLPF-176的分类命名为副干酪乳杆菌Lactobacillus paracasei,保藏号为CGMCC NO.18043,保藏日期为2019年6月27日,保藏单位为中国微生物菌种保藏管理委员会普通微生物中心,地址:北京市朝阳区北辰西路1号院3号,中国科学院微生物研究所,邮编:100101。
3.一种副干酪乳杆菌JLPF-176制备得到的治疗胃溃疡的产品,其特征在于,所述副干酪乳杆菌JLPF-176的分类命名为副干酪乳杆菌Lactobacillus paracasei,保藏号为CGMCCNO.18043,保藏日期为2019年6月27日,保藏单位为中国微生物菌种保藏管理委员会普通微生物中心,地址:北京市朝阳区北辰西路1号院3号,中国科学院微生物研究所,邮编:100101。
4.如权利要求2或3所述的产品,其特征在于,所述产品为内服制剂。
5.如权利要求2或3所述的产品,其特征在于,所述产品含有副干酪乳杆菌粉。
6.如权利要求5所述的产品,其特征在于,所述产品为副干酪乳杆菌粉与低聚异麦芽糖混合复配制成。
7.如权利要求5所述的产品,其特征在于,副干酪乳杆菌粉的活菌数为50亿/g-150亿/g、250亿/g、500亿/g、1000亿/g。
8.如权利要求5所述的产品,其特征在于,副干酪乳杆菌粉的制备方法为,将副干酪乳杆菌JLPF-176接种到MRS液体培养基平板中,1%接种量,在37℃条件下,兼性厌氧培养8-12小时,MRS菌液经过离心,真空冷冻干燥,获得副干酪乳杆菌粉。
9.如权利要求8所述的产品,其特征在于,所述MRS液体培养基为:蛋白胨10g、牛肉粉5g、酵母粉4g、K2HPO4•7H2O 2g、柠檬酸三铵2g、CH3COONa•3H2O 5g、葡萄糖20g、吐温80 1mL、MgSO4•7H2O 0.2g、MnSO4•4H2O 0.05g、琼脂15g、蒸馏水1000mL。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110066239.9A CN112386615B (zh) | 2021-01-19 | 2021-01-19 | 抑制幽门螺旋杆菌感染的副干酪乳杆菌jlpf-176的应用及产品 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110066239.9A CN112386615B (zh) | 2021-01-19 | 2021-01-19 | 抑制幽门螺旋杆菌感染的副干酪乳杆菌jlpf-176的应用及产品 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112386615A CN112386615A (zh) | 2021-02-23 |
CN112386615B true CN112386615B (zh) | 2021-04-06 |
Family
ID=74625320
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110066239.9A Active CN112386615B (zh) | 2021-01-19 | 2021-01-19 | 抑制幽门螺旋杆菌感染的副干酪乳杆菌jlpf-176的应用及产品 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112386615B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112940989B (zh) * | 2021-04-16 | 2021-09-03 | 吉林大学 | 一种具有益智功能的复合菌剂及其制备方法和应用 |
CN114404458B (zh) * | 2022-01-12 | 2024-01-19 | 诺佰克(武汉)生物科技有限公司 | 副干酪乳杆菌nbk-LC16在改善幽门螺杆菌感染及制备抗炎护胃产品中的应用 |
CN114958650A (zh) * | 2022-04-21 | 2022-08-30 | 四川高福记生物科技有限公司 | 一种防治幽门螺杆菌感染的副干酪乳杆菌及其组合物与应用 |
CN114836349B (zh) * | 2022-05-13 | 2023-05-12 | 江苏新申奥生物科技有限公司 | 拮抗幽门螺旋杆菌的嗜酸乳杆菌la16及其应用 |
CN117562930B (zh) * | 2024-01-15 | 2024-04-16 | 山东中科嘉亿生物工程有限公司 | 预防幽门螺杆菌感染的复合菌剂及其制备方法、应用 |
CN117778278B (zh) * | 2024-02-27 | 2024-05-03 | 山东中科嘉亿生物工程有限公司 | 一种复合乳酸菌青贮添加剂及其制备方法和应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108741090A (zh) * | 2018-08-28 | 2018-11-06 | 安徽谷益生物科技有限公司 | 一种抑制幽门螺旋杆菌的复合益生菌功能性食品 |
CN110959865B (zh) * | 2018-09-30 | 2021-07-09 | 内蒙古伊利实业集团股份有限公司 | 可调节胃肠道菌群平衡的副干酪乳杆菌k56的新应用 |
CN109480231A (zh) * | 2018-11-16 | 2019-03-19 | 广州普维君健药业有限公司 | 抗幽门螺杆菌的组合物及其应用 |
CN111849810B (zh) * | 2020-07-15 | 2021-04-20 | 浙江大学 | 拮抗幽门螺旋杆菌的乳酸菌zjuids03及其应用 |
-
2021
- 2021-01-19 CN CN202110066239.9A patent/CN112386615B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN112386615A (zh) | 2021-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112386615B (zh) | 抑制幽门螺旋杆菌感染的副干酪乳杆菌jlpf-176的应用及产品 | |
CN106834187B (zh) | 一种两歧双歧杆菌及其用途 | |
EP2509610B1 (en) | Compositions for the vaginal and oral administration of lactobacillus and uses thereof | |
CN1297653C (zh) | 包含戊糖乳杆菌菌株的组合物及其用途 | |
CN113832077B (zh) | 鼠李糖乳杆菌及其应用 | |
CN111011856A (zh) | 用于缓解胃病的组合物、其制备方法及用于缓解胃病的食品 | |
CN114908020B (zh) | 一种抗幽门螺旋杆菌感染的植物乳杆菌及其在食用本草酵素产品中的应用 | |
CN111548972A (zh) | 一株具有抗幽门螺旋杆菌功能的植物乳杆菌及其应用 | |
CN113005067B (zh) | 多功能复合益生菌制剂及其制备方法 | |
CN111548970A (zh) | 一株能够预防和/或治疗幽门螺杆菌感染的卷曲乳杆菌 | |
CN114774315B (zh) | 鼠李糖乳杆菌菌株LRa05在制备增强免疫力制品和/或缓解湿疹制品方面的用途 | |
CN114891675B (zh) | 胃源性植物乳杆菌lpf-01及其应用 | |
CN114540243A (zh) | 一种能够预防和或治疗幽门螺杆菌感染的鼠李糖乳杆菌及其应用 | |
CN111471626A (zh) | 一株能够抑制幽门螺杆菌的瑞士乳杆菌及其应用 | |
JP4540664B2 (ja) | グルタミン産生能を有する新規のBifidobacterium菌株 | |
CN114806958A (zh) | 胃源性凝结芽孢杆菌bcf-01及其应用 | |
CN112239739B (zh) | 一株可缓解etec致腹泻的植物乳杆菌及其应用 | |
CN113528367B (zh) | 一株具有预防腹泻和降解胆固醇功能的凝结芽孢杆菌 | |
TWI718394B (zh) | 一種乳酸菌組合物用於抑制胃幽門螺旋桿菌引發之胃炎及其用途 | |
CN111542330B (zh) | 肺炎链球菌感染的预防和/或治疗剂 | |
TWI792249B (zh) | 使用乳酸菌菌株的發酵培養物來治療和/或預防幽門螺旋桿菌感染的相關疾病 | |
CN115119940A (zh) | 嗜酸乳杆菌LA85和乳双歧杆菌BLa80在抑制幽门螺旋杆菌上的应用 | |
CN114806953A (zh) | 一种具有改善1型糖尿病特性的格氏乳杆菌 | |
TWI727378B (zh) | 嗜熱鏈球菌菌株st4及其抗發炎及預防癌症功效 | |
CN114574405B (zh) | 植物乳杆菌菌株wka86及其在制备防治口臭制品方面的用途与制品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Application and product of Lacticaseibacillus paracasei JLPF-176, which inhibits Helicobacter pylori infection Effective date of registration: 20230616 Granted publication date: 20210406 Pledgee: Qingzhou Shandong rural commercial bank Limited by Share Ltd. Pledgor: SHANDONG ZHONGKE-JIAYI BIO-ENGINEERING CO.,LTD. Registration number: Y2023980044147 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |